CMS Sets The Stage For New Medicare "Coverage With Evidence Development" Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
A rarely-used tool for gathering data on medical technologies will get a fresh look as the agency solicits public comment on how to make CED a more meaningful and effective part of its coverage decision-making process.
You may also be interested in...
Coverage With Evidence Development and Expedited Approvals: Policy Proposals For FDA and CMS
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.
Medicare CED Decisions By Local Contractors Would Be Unworkable, Drug Firms Argue
In comments to the Centers for Medicare and Medicaid Services, drug manufacturers also say CED should continue to be applied only “rarely” for drugs and biologics and should not apply to off-label uses.
Medicare CED Could Enable Expanded Use Of Expedited Drug Approvals, Policy Groups Suggest
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.